All News

Older adults with prior adenomas had slightly higher CRC risk, but 10-year CRC incidence was far outweighed by non-CRC mortality, supporting reduced surveillance colonoscopy use.

The disease progression of patients with MS had an association with their serum protein level.

Skin cancers arising from burn scars carry high recurrence and mortality risks, with squamous cell carcinoma considered most common.

There were about 70,000 Americans who died of drug overdoses in 2025, which continues a decline in drug overdoses that has lasted 3 years.

Exposure to adverse pregnancy outcomes may be associated with worse cardiovascular health and early arterial injury in young adulthood.

New research shows that celebrity endorsements can have a major impact on prescription patterns in the US.

A cohort-based mortality study found major state-by-state life expectancy gaps, with Southern states lagging in longevity gains.

In psoriatic arthritis, high BMI and smoking raise disease activity, while weight-focused lifestyle changes improve treat-to-target odds at one year.

New pediatric guidelines standardize radiation for metastatic rhabdomyosarcoma, detailing site-specific dosing to improve STS outcomes.

Global experts have renamed PCOS to PMOS, highlighting metabolic and endocrine risks—here’s what the name change means for diagnosis and care.

From rewriting drug approval standards to embedding AI in review workflows, former FDA commissioner Marty Makary, MD reshaped how evidence, speed, and access are balanced in US drug regulation.

Taiho submitted the supplemental new drug application in April 2025 for decitabine/cedazuridine and venetoclax, and the FDA accepted it for review in July 2025.

The complexity of MCL calls for personalized therapeutic strategies, but prior authorization protocols may not recognize distinct patient needs.

New real-world evidence presented at PQA 2026 exposes the blind spots in how medication adherence is measured, monitored, and misunderstood.

Deborah Doroshow, MD, PhD, discusses lung cancer trial access, targeted therapy advances, and treatment gaps in part 2 of her interview.

Pediatric Sequential Organ Failure Assessment may better predict death in ALL and sepsis, supporting earlier ICU intervention.

RBM20 truncating variants are associated with a milder, lower-penetrance form of dilated cardiomyopathy compared with other pathogenic genetic drive.

Digitalis glycosides lowered worsening heart failure events in patients with HFmrEF and HFrEF, but no mortality benefit was observed.

Circulating tumor DNA (ctDNA) detection is linked to worse survival outcomes in resectable melanoma, but high false-negative rates limit its use in surveillance or de-escalation.

Endometriosis increases ovarian cancer risk, but endometriosis-associated ovarian cancer shows favorable tumor characteristics and better survival.

Amid disagreements between the FDA and White House on drug approvals, vapes, and mifepristone, the tenure of Marty Makary, MD, as commissioner has come to an end.

Younger patients with early-onset CRC, especially men and racial and ethnic minority groups in urban areas, face a higher risk of cardiovascular death.

Eighteen Legionella cases were linked to Kaiser Santa Clara as officials investigate the source and infection risks.

The FDA announcement seeks nominees from the public for drug repurposing, leveraging AI signals to expand treatment options for rare diseases and other unmet needs.

In part 2, Deborah Doroshow, MD, PhD, discusses early clinical trial access, emerging lung cancer therapies, and barriers to equitable access.

Emphasizing the areas that can be improved when adherent to medication can be a means of keeping patients with retina diseases on their treatment, notes Anton M. Kolomeyer, MD, PhD.

Efgartigimod has recently been shown effective when investigated to treat ocular myasthenia gravis and juvenile myasthenia gravis.

Deep learning model beats breast density for 5-year breast cancer risk, informing supplemental screening decisions and personalized care.